American Home Products Corporation and Aventis Pharma have renegotiated their licensing agreement for trimegestone, a modern progestational molecule originated by Aventis for hormone replacement therapy. Under the new agreement, Wyeth-Ayerst Laboratories, the pharmaceutical division of AHP, has exclusive development and worldwide marketing rights for trimegestone for all indications and formulations except transdermal products. The rights Read more about AHP And Aventis Pharma Finalise HRT Agreement[…]